Faeth Therapeutics opened lower at $13.17, compared with its previous close of $13.35. In the last trading session, the stock traded between $11.41 and $13.17. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Faeth Therapeutics is now worth
$ 6.13
Resulting in a loss of
$ 93.87 (93.87%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-2.74 (-20.53%)
Day High
$13.17
Day Low
$11.41
Day Open
$13.17
Prev Close
$13.35
Volume
5,67,092
1W Return
-46.82%
1M Return
-54.26%
3M Return
-64.66%
6M Return
-48.82%
1Y Return
10.91%
Fundamentals
Market Cap ($ Mn)
274
PE Ratio
-
PB Ratio
5.05
PEG Ratio
-
ROE
-75.69%
ROCE
-78.12%
EPS (TTM)
$-0.79
Investment Returns
1 Week
-46.82%
1 Month
-54.26%
3 Months
-64.66%
6 Months
-48.82%
9 Months
20.01%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
Citigroup maintains Buy on Faeth Therapeutics, raises target to $60
Citigroup raised Faeth Therapeutics' price target to $60. Analyst Geoff Meacham maintained a Buy rating on the stock. The new target is $5 higher than the previous $55 estimate.
Confirmed objective response rate of 33% observed in Phase 2 trial. Disease control rate reached 83% in patients with PAM pathway mutations. Trial combined PIKTOR with paclitaxel for advanced endometrial cancer. Results presented from Study FTH-PIK-201 conducted with GOG Foundation.
3 days ago
3Nov
Faeth Therapeutics Q3 Results: Loss widens to $(0.79), misses estimates
Faeth Therapeutics posted a Q3 loss of $(0.79) per share. Result missed the analyst consensus estimate of $(0.71) by 11.27%. Loss per share widened 78.18% YoY from $(3.62) in the prior year.
9 days ago
16Oct
William Blair initiates Faeth Therapeutics with Outperform rating
William Blair initiated coverage on Faeth Therapeutics. Analyst Alethia Young assigned an Outperform rating. No specific price target or financial data was provided in the source.
27 days ago
15Jun
BTIG reiterates Buy on Sensei Biotherapeutics, maintains $55 target
BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Sensei Biotherapeutics (NASDAQ: SNSE) with a maintained price target of $55, reflecting continued confidence in the company's valuation.
